Efficacy News and Research

RSS
Merck signs two licensing agreements for investigational HIV drug candidates

Merck signs two licensing agreements for investigational HIV drug candidates

Elan second quarter total revenue increases 6% to $288.0 million

Elan second quarter total revenue increases 6% to $288.0 million

Favorable results from BioCryst’s ulodesine plus allopurinol Phase 2b trial on gout

Favorable results from BioCryst’s ulodesine plus allopurinol Phase 2b trial on gout

Biokine receives FDA Orphan Drug designation for BKT140 to treat hematological cancers

Biokine receives FDA Orphan Drug designation for BKT140 to treat hematological cancers

VEGF inhibitor fails to improve nonsquamous NSCLC overall survival

VEGF inhibitor fails to improve nonsquamous NSCLC overall survival

Stromal cells offer chemotherapy clue in early lung cancer

Stromal cells offer chemotherapy clue in early lung cancer

Findings cast doubt on sepsis drug withdrawal

Findings cast doubt on sepsis drug withdrawal

FDA approves 152 antiretroviral drugs in association with PEPFAR to treat HIV/AIDS

FDA approves 152 antiretroviral drugs in association with PEPFAR to treat HIV/AIDS

Topline results from first of four Phase 3 studies of Pfizer's bapineuzumab for Alzheimer's

Topline results from first of four Phase 3 studies of Pfizer's bapineuzumab for Alzheimer's

Implementing population level changes could avoid up to 50% of deaths from CVD

Implementing population level changes could avoid up to 50% of deaths from CVD

Debiopharm initiates Debio 8206 Phase III study on advanced prostate cancer

Debiopharm initiates Debio 8206 Phase III study on advanced prostate cancer

Forest Pharmaceuticals receives FDA approval for Tudorza Pressair to treat COPD

Forest Pharmaceuticals receives FDA approval for Tudorza Pressair to treat COPD

Once-daily Gralise significantly reduces pain intensity in PHN patients

Once-daily Gralise significantly reduces pain intensity in PHN patients

Top-line results in Pfizer's Lyrica long term safety study for Generalized Anxiety Disorder

Top-line results in Pfizer's Lyrica long term safety study for Generalized Anxiety Disorder

Positive results from BrainStorm's interim NurOwn stem cell therapy clinical trial for ALS

Positive results from BrainStorm's interim NurOwn stem cell therapy clinical trial for ALS

Herbal therapy no alternative in HCV infection

Herbal therapy no alternative in HCV infection

Pneumococcal revaccination needed in kidney transplant patients

Pneumococcal revaccination needed in kidney transplant patients

Linagliptin safe and effective for long-term management of type 2 diabetes

Linagliptin safe and effective for long-term management of type 2 diabetes

Bayer, Onyx and Astellas announce results from Tarceva plus Nexavar Phase 3 trial on HCC

Bayer, Onyx and Astellas announce results from Tarceva plus Nexavar Phase 3 trial on HCC

International Congress on Natural Products Research to be held in New York City

International Congress on Natural Products Research to be held in New York City

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.